Advertisement

Topics

Flexion Therapeutics sees revenue jump 36% in preliminary 4Q results

12:02 EST 3 Jan 2019 | Proactive Investors

The biotech expects revenue from Zilretta, its osteoarthritis injectable treatment, to be between $65 million and $80 million

Original Article: Flexion Therapeutics sees revenue jump 36% in preliminary 4Q results

NEXT ARTICLE

More From BioPortfolio on "Flexion Therapeutics sees revenue jump 36% in preliminary 4Q results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Arthritis
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...